Cerebrospinal fluid neuropeptides in Alzheimer's disease and vascular dementia.
Heilig. M M; Sjögren. M M; Blennow. K K; Ekman. R R; Wallin. A A
Key Findings
- s and vascular dementia.",
- , "Delta sleep‑inducing peptide (DSIP) was slightly increased in Alzheimer
- Neuropeptide Y (NPY) showed no difference between patients and healthy controls.
- Peptide levels did not correlate with disease duration, and only BEND correlated with dementia severity.
Practical Outcomes
- For biohackers, the findings offer little direct guidance. The slight rise in DSIP in Alzheimer's patients does not suggest a benefit for healthy individuals seeking better sleep or longevity, and no dosage or protocol recommendations emerge. Overall, the study is more of a disease‑mechanism observation than a usable health‑optimization insight.
Summary
The study measured several brain chemicals in spinal fluid from older people with Alzheimer's or vascular dementia and compared them to healthy seniors. It found that most of the chemicals were lower in the diseased groups, while the sleep‑related peptide DSIP was a bit higher in Alzheimer's patients but unchanged in vascular dementia. The changes didn’t link to how long someone had been sick.
Abstract
Cerebrospinal fluid (CSF) levels of several neuropeptides have been suggested as candidate markers in neurodegenerative disorders. We have examined the levels of corticotropin-releasing hormone (CRH), beta-endorphine (BEND), delta sleep-inducing peptide (DSIP), somatostatin (SRIF), and neuropeptide Y (NPY) in CSF samples obtained under highly standardized conditions from healthy aged controls and from patients suffering from Alzheimer's disease (AD) or vascular dementia (VAD). The influence of some potentially confounding factors was evaluated. CRH and BEND were markedly decreased in both AD and VAD patients, and BEND levels correlated negatively with degree of dementia within the patient population. SRIF was decreased in both AD and VAD patients. DSIP was slightly increased in AD, but not in VAD. NPY did not differ between groups. For none of the peptides did CSF concentrations correlate significantly with duration of illness, nor, with the exception of BEND, with its degree. Present data do not support the hypothesis that specific neuropeptide changes occur in different neurodegenerative disorders, but are in agreement with previous reports suggesting that neuropeptide systems are differentially affected by neurodegeneration.
Study Information
pubmed
1995
1995-08-15T00:00:00.000Z
10.1016/0006-3223(94)00239-y